Currently the Founder and President of Merkeley Ventures. Merkeley Ventures is a portfolio holding company for multiple investments across a diverse range of assets including multifamily, agriculture, land development, self storage and health security. The diverse portfolio reflects the restless nature of the team, the culture of innovation fostered within each asset and the focus across the portfolio of leveraging innovative technology and practices to drive value and impacthttps://merkeleyventures.com/

An experienced innovator with a track record of designing and launching novel business models across government to enhance National Health Security through the establishment of unique public private partnerships:-In 2018, led the design and startup of BARDA's new Division of Research, Innovation and Ventures (DRIVe). DRIVe is leading the transformation of health security innovation by identifying, investing-in and accelerating disruptive health security innovation to protect Americans from 21st-century health security threats. (www.drive.hhs.gov)- As a Co-Founder, established and launched the U.S Department of Health and Human Services (HHS) CARB-X initiative in 2016. CARB-X is now the world’s largest global antibacterial public private partnership responsible for “Xccelerating Global Antibacterial Innovation" with over $550M in non-dilutive capital and over $800M in follow-on private capital investment into Powered by CARB-X Companies (www.CARB-X.org)

Experienced innovator and leader charged with advancing research, development and forming novel public private partnerships in Health Security. Division of Research, Innovation and Ventures (DRIVe) is transforming health security innovation at the Biomedical Advanced Research and Development Authority (BARDA) to protect Americans from 21st-century health security threats by identifying, investing-in and accelerating disruptive health security innovations. (www.drive.hhs.gov)- Leading DRIVe’s strategic approach to transforming health security innovation through the formulation of novel public-private partnerships, including the use of non-dilutive and dilutive investment vehicles- Responsible for empowering a team of restless innovators to revolutionize prevention, detection, and response to our biggest national health security threats by developing innovative technologies and practices for transformative solutions- Providing oversight of DRIVe Innovation Funding decisions, Internal and External Engagement and positioning DRIVe to achieve once-unthinkable solutions to health security challenges – through the power of collaboration and innovation- Co-Founder of the U.S Department of Health and Human Services (HHS) CARB-X initiative. CARB-X initiative is the world’s largest global antibacterial public private partnership responsible for “Xccelerating Global Antibacterial Innovation” with over $500M in funding and excess of $500M of follow-on private capital investment into CARB-X companies. Continuing to serve as a member of CARB-X's Joint Oversight Committee (JOC)

Co-Founder of the U.S Department of Health and Human Services (HHS) CARB-X initiative. The world’s largest global antibacterial public private partnership responsible for “Xccelerating Global Antibacterial Innovation"-Responsible for developing and pitching the conceptual design for HHS's CARB Incubator/Accelerator initiative (CARB-X) as part of the 2014 United States Government’s National Strategy for Combating Antibiotic Resistant Bacteria (CARB)-Led the Biomedical Advanced Research and Development Authority’s (BARDA) pre-award activities for CARB-X including the strategy of encouraging partners to leverage non-dilutive funding from stakeholders (cost share)-Leading HHS's post award management of CARB-X and interagency coordination with NIAID-A member of CABR-X's Joint Oversight Committee (JOC)-Responsible for identifying strategies to expand, scale and sustain CARB-X to align with BARDA's long-term vision for CARB-X

Supporting the U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority’s (BARDA) effort to accelerate the advanced research and development, procurement, stockpile and sustainment of medical countermeasures (MCM) against biological, chemical, radiological, and nuclear (CBRN) agents under Project BioShield (PBS)-Assisted in the strategic planning and launch in 2010 of BARDA’s Broad Spectrum Antimicrobials (BSA) Program with the goal to revitalize the antibiotic development pipeline so that critically needed novel antibiotics are developed to combat the rise of antibiotic resistant infections. As a project officer within the BSA program, provides daily Program Management, Portfolio Management, Strategic Analysis, Acquisition, Sustainment and Scientific expertise to support the expansion of the BSA portfolio-Responsible for leading BARDA’s public private partnership supporting the late stage development, manufacturing and acquisition of a Smallpox Antiviral for the Strategic National Stockpile (SNS). Responsible for leading the interagency effort that successfully delivered a Smallpox Antiviral to the SNS and DOD starting in March 2013-Recipient of the United States Army’s “Achievement Medal for Civilian Service” for leading an effort to share interagency government resources, save taxpayers money and provide a new capability to protect US Forces-Supported and/or led the pre-award efforts of over $1 Billion in acquisition since June 2010, leveraging multiple acquisition mechanisms (RFP, BAA, IDIQ, IAA, OTA)-Leading an integrated matrix team overseeing a portfolio of broad spectrum antimicrobials in excess of $700 Million -Led BARDA’s pre-award acquisition planning effort to establish a Strategic Investor which intended to utilize HHS’s Other Transaction Authority (OTA)-Led BARDA’s working group to establish a Total Life Cycle Costs definition and developed a cost tool to estimate drug development costs

Implementation of the Department of Defense, Cooperative Threat Reduction (CTR), Biological Threat Reduction Program (BTRP) in the country of Kazakhstan. Responsible for providing scientific subject matter expertise and program management support. The program supports the planning, design, implementation and maintenance of Kazakhstan’s public health infrastructure including disease surveillance and reporting in accordance with international regulations and guidelines

Researched Dual-Use of Biotechnology: Implementation of a novel analytical tool to assess the likelihood that a nation’s civilian biotech sector was being used for military dual use capability. Including the use of analytical tools to examine the intent of the users through a multi-factorial axis.